Strata Critical Medical (SRTA) Cash & Equivalents (2019 - 2026)

Strata Critical Medical (SRTA) has 8 years of Cash & Equivalents data on file, last reported at $58.7 million in Q1 2026.

• Quarterly Cash & Equivalents rose 68.6% year-over-year to $58.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.7 million (up 68.6% YoY) and the FY2025 annual result came in at $31.0 million, up 92.68% from the prior year.
• Cash & Equivalents improved to $58.7 million in Q1 2026 per SRTA's latest filing, from $31.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $186.6 million in Q2 2022 and bottomed at $263000.0 in Q3 2025.
• The 5-year median for Cash & Equivalents is $34.8 million (2025), against an average of $37.9 million.
• The widest annual swing landed in 2023, when Cash & Equivalents soared 1572.24%; it then plunged 98.69% in 2025.
• Tracing SRTA's Cash & Equivalents over 5 years: stood at $3.1 million in 2022, then tumbled by 62.79% to $1.1 million in 2023, then surged by 1300.0% to $16.1 million in 2024, then jumped by 92.68% to $31.0 million in 2025, then surged by 89.62% to $58.7 million in 2026.
• Per Business Quant, the three latest SRTA Cash & Equivalents figures stand at $58.7 million (Q1 2026), $31.0 million (Q4 2025), and $263000.0 (Q3 2025).

Peer Comparison